A key source of nucleic acids, including RNA, exosomes are cell messengers found in all living cells and carried throughout the body via biofluids, such as plasma, urine and cerebrospinal fluid. Using exosomes, researchers can achieve real-time access to comprehensive molecular information about cells in the body without needing direct access to the cells.
We are establishing partnerships with industry leaders to make our proprietary exosome-based technology platform available for research use. Our research kits are designed to be used by academic and industry researchers for biomarker discovery, liquid biopsy and clinical diagnostic development, and the advancement of targeted therapies. Currently, kits are available to isolate and extract exosomal RNA (exoRNA) from serum/plasma and urine samples.
Our proprietary technology for the purification of exoRNA from serum/plasma samples is currently available for research use in exoRNeasy Serum/Plasma kits marketed by QIAGEN. These kits use a simple spin column method to isolate exosomes and other extracellular vesicles out of serum, plasma, cell culture supernatant, and other biological fluids. View partnership announcement.
The exoRNeasy Serum/Plasma kits can be purchased on the QIAGEN website in Midi size (for samples from 0.1 to 1 ml) and in Maxi size (for samples from 0.2 to 4ml).
Promega Corporation will be the exclusive supplier of Exosome Diagnostics’ Urine Clinical Sample Concentrator Kit, which incorporates our proprietary method for concentration of urinary exosomes, a standardized approach for providing clinical laboratories access to high quality preparations suitable for molecular diagnostics. The kit will be used to process urine samples for clinical trials in genitourinary disorders, including prostate cancer. View partnership announcement.